🔴 Scholar Rock is trading 8.1% down today after Barclays downgraded shares to Equal Weight

Scholar Rock is trading 8.1% down at $47.65 after Barclays downgraded the shares to Equal Weight from Overweight.

• Barclays raised its price target to $58 following ISEMBYLD’s FDA approval.
• The decline extends a post-approval pullback as investors shift attention to launch execution and commercialization.
• The broader market is modestly lower, but analyst action and company-specific repricing appear more significant drivers.